SEC Info℠ | Home | Search | My Interests | Help | Sign In | Please Sign In | ||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 11/13/23 Bristol-Myers Squibb Co. 8-K:8,9 10/30/23 14:1M Broadridge Fin’l So… Inc |
Document/Exhibit Description Pages Size 1: 8-K Current Report HTML 59K 2: EX-1.1 Underwriting Agreement or Conflict Minerals Report HTML 224K 3: EX-4.1 Instrument Defining the Rights of Security Holders HTML 437K 4: EX-5.1 Opinion of Counsel re: Legality HTML 18K 9: R1 Document and Entity Information HTML 55K 12: XML IDEA XML File -- Filing Summary XML 12K 10: XML XBRL Instance -- ny20014138x1_8k_htm XML 25K 11: EXCEL IDEA Workbook of Financial Report Info XLSX 8K 6: EX-101.DEF XBRL Definitions -- bmy-20231030_def XML 53K 7: EX-101.LAB XBRL Labels -- bmy-20231030_lab XML 79K 8: EX-101.PRE XBRL Presentations -- bmy-20231030_pre XML 57K 5: EX-101.SCH XBRL Schema -- bmy-20231030 XSD 17K 13: JSON XBRL Instance as JSON Data -- MetaLinks 16± 23K 14: ZIP XBRL Zipped Folder -- 0001140361-23-052908-xbrl Zip 137K
i Delaware
|
i 22-0790350
|
|||
(State or other jurisdiction of incorporation or organization)
|
(Commission File Number)
|
(I.R.S Employer Identification No.)
|
i ☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
i ☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
i ☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
i ☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
||
i Common Stock, $0.10 Par Value
|
i BMY
|
i New York Stock Exchange
|
||
i 1.000% Notes due 2025
|
i BMY25
|
i New York Stock Exchange
|
||
i 1.750% Notes due 2035
|
i BMY35
|
i New York Stock Exchange
|
||
i Celgene Contingent Value Rights
|
i CELG RT
|
i New York Stock Exchange
|
Series of Notes
|
Interest Rate
|
Maturity Date
|
Interest Payment Dates
|
2031 Notes
|
5.750%
|
February 1 and August 1,
beginning on February 1, 2024
|
|
2033 Notes
|
5.900%
|
May 15 and November 15,
beginning on May 15, 2024
|
|
2053 Notes
|
6.250%
|
November 15, 2053
|
May 15 and November 15,
beginning on May 15, 2024
|
2063 Notes
|
6.400%
|
November 15, 2063
|
May 15 and November 15,
beginning on May 15, 2024
|
Exhibit No.
|
Description
|
|
1.1
|
Underwriting Agreement, dated October 30, 2023, by and among Bristol-Myers Squibb Company and the underwriters named therein.
|
|
4.1
|
Fourteenth Supplemental Indenture, dated as of November 13, 2023, by and between Bristol-Myers Squibb Company and The Bank of New York Mellon, as Trustee, to the Indenture dated as of June 1, 1993.
|
|
4.2
|
Form of $1,000,000,000 5.750% Notes due 2031 (included as Exhibit A to Exhibit 4.1)
|
|
4.3
|
Form of $1,000,000,000 5.900% Notes due 2033 (included as Exhibit B to Exhibit 4.1)
|
|
4.4
|
Form of $1,250,000,000 6.250% Notes due 2053 (included as Exhibit C to Exhibit 4.1)
|
|
4.5
|
Form of $1,250,000,000 6.400% Notes due 2063 (included as Exhibit D to Exhibit 4.1)
|
|
5.1
|
Opinion of Kirkland & Ellis LLP.
|
|
23.1
|
Consent of Kirkland & Ellis LLP (included in Exhibit 5.1 of this Current Report on Form 8-K).
|
|
104
|
The cover page from this Current Report on Form 8-K formatted in Inline XBRL (included as Exhibit 101).
|
Exhibit No.
|
Description
|
|
Underwriting Agreement, dated October 30, 2023, by and among Bristol-Myers Squibb Company and the underwriters named therein.
|
||
Fourteenth Supplemental Indenture, dated as of November 13, 2023, by and between Bristol-Myers Squibb Company and The Bank of New York Mellon, as Trustee, to the Indenture dated as of June 1, 1993.
|
||
Form of $1,000,000,000 5.750% Notes due 2031 (included as Exhibit A to Exhibit 4.1)
|
||
Form of $1,000,000,000 5.900% Notes due 2033 (included as Exhibit B to Exhibit 4.1)
|
||
Form of $1,250,000,000 6.250% Notes due 2053 (included as Exhibit C to Exhibit 4.1)
|
||
Form of $1,250,000,000 6.400% Notes due 2063 (included as Exhibit D to Exhibit 4.1)
|
||
Opinion of Kirkland & Ellis LLP.
|
||
Consent of Kirkland & Ellis LLP (included in Exhibit 5.1 of this Current Report on Form 8-K).
|
||
104
|
The cover page from this Current Report on Form 8-K formatted in Inline XBRL (included as Exhibit 101).
|
BRISTOL-MYERS SQUIBB COMPANY
|
||
Dated: November 13, 2023
|
By:
|
|
Name:
|
||
Title:
|
Corporate Secretary
|
This ‘8-K’ Filing | Date | Other Filings | ||
---|---|---|---|---|
11/15/33 | ||||
2/1/31 | ||||
5/15/24 | ||||
2/1/24 | ||||
Filed on: | 11/13/23 | |||
11/1/23 | 4, 424B5 | |||
For Period end: | 10/30/23 | 424B3, FWP | ||
12/13/21 | S-3ASR | |||
6/3/93 | ||||
6/1/93 | ||||
5/27/93 | ||||
List all Filings |
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 2/13/24 Bristol-Myers Squibb Co. 10-K 12/31/23 148:22M |